Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing. Norwest Venture Partners led the round with participation from Pivotal bioVenture Partners, F-Prime Capital, Novo Holdings A/S, RiverVest Venture Partners and TPG Biotech.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: